Bicara Therapeutics Inc. Common Stock
N/A
USD
N/A
N/A
...
Chart
Financials
Description
BCAX Company Description
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
BCAX Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view BCAX Smart Score
Score Breakdown
Bull Case vs Bear Case
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
Bulls Say:
The Bulls Say summary highlights positive aspects of the stock.
Bears Say:
The Bears Say summary points out potential risks and negative aspects of the stock.
Show More
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of BCAX by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by BCAX's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
Government Contracts
Federal grants, loans, and purchases
WallStreetBets
Number of mentions of BCAX in WallStreetBets Daily Discussion
BCAX News
Recent insights relating to BCAX
CNBC Recommendations
Recent picks made for BCAX stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in BCAX
Corporate Flights
Flights by private jets registered to BCAX
Our Analysis